L, C., C, K., SJ, C., SL, U., MA, W., MAT, H., . . . H, D. (2017). Pharmacokinetics and pharmacodynamics modeling of lonafarnib in patients with chronic hepatitis delta virus infection. Hepatology communications, 1(4), 288. https://doi.org/10.1002/hep4.1043
Chicago Style (17th ed.) CitationL, Canini, et al. "Pharmacokinetics and Pharmacodynamics Modeling of Lonafarnib in Patients with Chronic Hepatitis Delta Virus Infection." Hepatology Communications 1, no. 4 (2017): 288. https://doi.org/10.1002/hep4.1043.
MLA (9th ed.) CitationL, Canini, et al. "Pharmacokinetics and Pharmacodynamics Modeling of Lonafarnib in Patients with Chronic Hepatitis Delta Virus Infection." Hepatology Communications, vol. 1, no. 4, 2017, p. 288, https://doi.org/10.1002/hep4.1043.
Warning: These citations may not always be 100% accurate.
